Inhibition of spontaneous breast cancer metastasis by anti-Thomsen- Friedenreich antigen monoclonal antibody JAA-F11

Neoplasia

Volumn 8, Issue 11, 2006, Pages 939-948

  Heimburg, Jamie ^a   Yan, Jun ^a   Morey, Susan ^a   Glinskii, Olga V ^b   Huxley, Virginia H ^b   Wild, Linda ^a   Klick, Robert ^a   Roy, Rene ^c   Glinsky, Vladislav V ^b,d   Rittenhouse Olson, Kate ^a  

^a UNIVERSITY AT BUFFALO   (United States)

^b University of Missouri   (United States)

^c UNIVERSITÉ DU QUÉBEC À MONTRÉAL   (Canada)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Adhesion; Breast carcinoma; Metastasis; Monoclonal antibody; TF Ag

Indexed keywords

MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY JAA F11; THOMSEN FRIEDENREICH ANTIGEN; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BREAST CANCER; BREAST METASTASIS; CANCER GROWTH; CANCER INHIBITION; CANCER SURVIVAL; CELL ADHESION; CONTROLLED STUDY; CYTOTOXICITY; DRUG INHIBITION; FEMALE; HUMAN; HUMAN CELL; LUNG METASTASIS; METASTASIS; METASTASIS INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 33750728383     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.06493     Document Type: Article

References (47)

1. Dippold W, Steinborn A, and Meyer zum Buschenfelde KH (1990). The role of the Thomsen-Friedenreich antigen as a tumor-associated molecule. Environ Health Perspect 88, 255-257.
2. Maclean GD and Longenecker BM (1991). Clinical significance of the Thomsen-Friedenreich antigen. Semin Cancer Biol 2, 433-439.
3. Springer GF and Desai PR (1982). Extent of desialylation of blood group MM, NN, and MN antigens required for reactivity with human anti-T antibody and Arachis hypogaea lectin. J Biol Chem 257 (6), 2744-2746.
4. Springer GF, Desai PR, and Banatwala I (1975). Blood group MN antigens and precursors in normal and malignant human breast glandular tissue. J Natl Cancer Inst 54 (2), 335-339.
5. Glinsky VV, Glinsky GV, Rittenhouse-Olson K, Huflejt ME, Glinskii OV, Deutscher SL, and Quinn TP (2001). The role of Thomsen-Friedenreich antigen in adhesion of human breast and prostate cancer cells to the endothelium. Cancer Res 61, 4851-4857.
6. Takanami I (1999). Expression of Thomsen-Friedenreich antigen as a marker of poor prognosis in pulmonary adenocarcinoma. Oncol Rep 6, 341-344.
7. Springer GF (1984). T and Tn, general carcinoma autoantigens. Science 224, 1198-1206.
8. Wolf MF, Koerner U, and Schumaker K (1986). Specificity of reagents directed to the Thomsen-Friedenreich antigen and their capacity to bind to the surface of human carcinoma cell lines. Cancer Res 46, 1779-1782.
9. Wolf MF, Ludwig A, Fritz P, and Schumacher K (1988). Increased expression of Thomsen-Friedenreich antigens during tumor progression in breast cancer patients. Tumour Biol 9, 190-194.
10. Zanetti M, Lenert G, and Springer GF (1993). Idiotypes of pre-existing human anti-carcinoma anti-T and anti-Tn antibodies. Int Immunol 5, 113-119.
11. Springer GF, Desai P, Tegtmeyer H, Carlstedt SC, and Scanlon EF (1994). T/Tn antigen vaccine is effective and safe in preventing recurrence of advanced human breast carcinoma. Cancer Biother 9, 7-15.
12. Avichezer D, Springer GF, Schechter B, and Arnon R (1997). Immunoreactivities of polyclonal and monoclonal anti-T and anti-Tn antibodies with human carcinoma cells, grown in vitro and in a xenograft model. Int J Cancer 72 (1), 119-127 ([published erratum appears in Int J Cancer 72 (5), 918]).
13. Gabius HJ, Schroter C, Gabius S, Brinck U, and Tietze L-F (1990). Binding of T antigen-bearing neoglycoprotein and peanut agglutinin to cultured tumor cells and breast carcinomas. J Histochem Cytochem 38, 1625-1631.
14. Choufani G, Nagy N, Saussez S, Marchant H, Bisschop P, Burchert M, Danguy A, Louryan S, Salmon I, Gabius HJ, et al. (1999). The levels of expression of galectin-1, galectin-3, and the Thomsen-Friedenreich antigen and their binding sites. Cancer 86, 2353-2363.
15. Shigeoka H, Karsten U, Okuno K, and Yasutomi M (1999). Inhibition of liver metastasis from neuraminidase treated colon 26 cells by an anti - Thomsen-Friedenreich specific monoclonal antibody. Tumour Biol 20 (3), 139-146.
16. Kishikawa T, Ghazizadeh M, Sasaki Y, and Springer G (1999). Specific role of T and Tn tumor-associated antigens in adhesion between a human breast carcinoma line and a normal human breast epithelial cell line. Jpn J Cancer Res 90, 326-332.
17. Glinsky VV, Huflejt ME, Glinsky GV, Deutscher SL, and Quinn TP (2000). Effects of Thomsen-Friedenreich antigen-specific peptide P-30 on β-galactoside-mediated homotypic aggregation and adhesion to the endothelium of MDA-MB-435 human breast carcinoma cells. Cancer Res 60, 2584-2588.
18. Springer GF, Cheingsong-Popov R, Schirrmacher V, Desait PR, and Tegtmeyer H (1983). Proposed molecular basis of murine tumor cell-hepatocyte interaction. J Biol Chem 258, 5702-5706.
19. Springer GF (1995). T and Tn pancarcinoma markers autoantigenic adhesion molecules in pathogenesis, prebiopsy carcinoma detection, and long term breast carcinoma immunotherapy. Crit Rev Oncol 6, 57-85.
20. Schirrmacher V, Cheingsong-Popov R, and Arnheiter H (1980). Hepatocyte-tumor cell interaction in vitro. J Exp Med 151 (4), 984-989.
21. Kurtenkov O, Klaamas K, Rittenhouse-Olson K, Brjalin V, Miljukhina L, Shljapnikova L, and Engstrand L (2002). Expression of tumor-associated Thomsen-Friedenreich (T) antigen in Helicobacter pylori and modulation of T Ag specific immune response in infected individuals. Immunol Invest 31, 191-204.
22. O'Boyle KP, Zamore R, Adluri S, Cohen A, Kemeny N, Welt S, Lloyd KO, Oettgen HF, Old LJ, and Livingston PO (1992). Immunization of colorectal cancer patients with modified ovine submaxillary gland mucin and adjuvants induces IgM and IgG antibodies to sialylated Tn. Cancer Res 52 (20), 5663-5667.
23. O'Boyle KP, Markowitz AL, Khorshidi M, Lalezari P, Longenecker BM, Lloyd KO, Welt S, and Wright KE (1996). Specificity analysis of murine monoclonal antibodies reactive with Tn, sialylated Tn, T and monosialylated (2-6) T antigens. Hybridoma 15 (6), 401-408.
24. Moase EH, Qi W, Ishida T, Gabos Z, Longenecker BM, Zimmermann GL, Ding L, Krantz M, and Allen TM (2000). Clinical outcome of breast and ovarian cancer patients treated with high-dose chemotherapy, autologous stem cell rescue and THERATOPE: STn-KLH cancer vaccine. Bone Marrow Transplant 25 (12), 1233-1241.
25. Holmberg LA and Sandmaier BM (2001). Theratope vaccine (STn-KLH). Expert Opin Biol Ther 1 (5), 881-891.
26. Longenecker B and Willans D (1987). Monoclonal antibodies and synthetic tumor associated glycoconjugates in the study of the expression of TF like and Tn like antigens on human cancers. J Natl Cancer Inst 78, 489-496.
27. Gilewski T, Ragupathi G, Bhuta S, Williams LJ, Musselli C, Zhang XF, Bornmann WG, Spassova M, Bencsath KP, Panageas KS, et al. (2001). Immunization of metastatic breast cancer patients with a fully synthetic Globo H conjugate: a phase I trial. Proc Natl Acad Sci USA 98 (6), 3270-3275.
28. Rittenhouse-Diakun K, Xia Z, Pickhardt D, Morey S, Baek M-G, and Roy R (1998). Development and characterization of monoclonal antibody to T-antigen: GalB1-3GalNAc-alpha-O. Hybridoma 17 (2), 165-173.
29. 99mtechnetium mAb-170H.82 (Tru-Scint AD). Breast Cancer Res Treat 45 (1), 29-37.
30. Irazoqui FJ, Jansson B, Lopez PH, and Nores GA (2001). Correlative fine specificity of several Thomsen-Friedenreich disaccharide-binding proteins with an effect on tumor cell proliferation. J Biochem (Tokyo) 130 (1), 33-37.
31. Yu LG, Jansson B, Fernig DG, Milton JD, Smith JA, Gerasimenko OV, Jones M, and Rhodes JM (1997). Stimulation of proliferation in human colon cancer by human monoclonal antibodies against the TF antigen (galactose beta 1-3 N-acetyl-galactosamine). Int J Cancer 73 (3), 424-431.
32. Yu LG, Milton JD, Fernig DG, and Rhodes JM (2001). Opposite effects on human colon cancer cell proliferation of two dietary Thomsen-Friedenreich antigen-binding lectins. J Cell Physiol 186 (2), 282-287.
33. Glinskii OV, Huxley VH, Turk JR, Deutscher SL, Quinn TP, Pienta KJ, and Glinsky VV (2003). Continuous real time ex vivo epifluorescent video microscopy for studying cancer cell interactions with dura mater microvasculature. Clin Exp Metastasis 20, 451-458.
34. Pulaski BA and Ostrand-Rosenberg S (1998). Reduction of established spontaneous mammary carcinoma metastases following immunotherapy with major histocompatibility complex class II and B7.1 cell-based tumor vaccines. Cancer Res 58, 1486-1493.
35. Pulaski BA, Terman DS, Khan S, Muller E, and Ostrand-Rosenberg S (2000). Cooperativity of Staphylococcal aureus enterotoxin B superantigen, major histocompatibility complex class II, and CD80 for immunotherapy of advanced spontaneous metastasis in a clinically relevant postoperative mouse breast cancer model. Cancer Res 60, 2710-2715.
36. Aslakson CJ and Miller FR (1992). Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res 52, 1399-1405.
37. Rood PML, Calafat J, Von dem Borne AEGKR, Gerritsen WR, and van der Schoot CE (2000). Immortalisation of human bone marrow endothelial cells: characterization of new cell lines. Eur J Clin Invest 30, 618-629.
38. Johnson TA and Press OW (2000). Synergistic cytotoxicity of iodine-131-anti-CD20 monoclonal antibodies and chemotherapy for treatment of B-cell lymphomas. Int J Cancer 85 (1), 104-112.
39. O'Toole SA, Sheppard BL, McGuinness EP, Gleeson NC, Yoneda M, and Bonnar J (2003). The MTT assay as an indicator of chemosensitivity/ resistance in malignant gynaecological tumours. Cancer Detect Prev 27 (1), 47-54.
40. Howard DR and Batsakis JG (1980). Cytostructural localization of a tumor-associated antigen. Science 210, 201-203.
41. Howard DR, Ferguson P, and Batsakis JG (1981). Carcinoma-associated cytostructural antigenic alterations. Detection by lectin binding. Cancer 47, 2872-2877.
42. Glinskii OV, Turk JR, Pienta KJ, Huxley VH, and Glinsky VV (2004). Evidence of porcine and human endothelium activation by cancer-associated carbohydrates expressed on glycoproteins and tumor cells. J Physiol (Lond) 554, 89-99.
43. Hsu DK and Liu FT (2004). Regulation of cellular homeostasis by galectins. Glycoconj J 19 (7-9), 507-515.
44. Schwarz RE, Wojciechowicz DC, Picon AI, Schwarz MA, and Paty PB (1999). Wheatgerm agglutinin-mediated toxicity in pancreatic cancer cells. Br J Cancer 80 (11), 1754-1762.
45. Glinskii OV, Huxley VH, Glinsky GV, Pienta KJ, Raz A, and Glinsky VV (2005). Mechanical entrapment is insufficient and intercellular adhesion is essential for metastatic cell arrest in distant organs. Neoplasia 5, 522-527.
46. Glinsky VV, Glinsky GV, Glinskii OV, Huxley VH, Turk JR, Mossine VV, Deutscher SL, Pienta KJ, and Quinn TP (2003). Intravascular metastatic cancer cell homotypic aggregation at the sites of primary attachment to the endothelium. Cancer Res 63 (13), 3805-3811.
47. National Comprehensive Cancer Network (NCCN) (2005). Clinical Practice Guidelines for Breast Cancer, Version 2 (http://www.nccn.org/professionals/ physician_gls/PDF/breast.pdf; updated 5/31/05).